

DAFTAR PUSTAKA

1. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: A critical review. *Autoimmun Rev.* 2012;12:174–94.
2. Mina R. Pediatric Lupus – Are There Differences in Presentation, Genetics, Response to Therapy, Damage Accrual Compared to Adult Lupus?
3. Hersh AO, Von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. Differences in Long-Term Disease Activity and Treatment of Adult Patients With Childhood-and Adult-Onset Systemic Lupus Erythematosus. *Arthritis Rheum.* 2009;15:13–20.
4. Hafeez F, Tarar AM, Saleem R. Lupus nephritis in children. *J Coll Physicians Surg Pakistan.* 2008;18:17–21.
5. Ben Ariba Y, Chargui S, Ajili F, Maiza M, Sayhi S, Louzir B, et al. Hypertension in Lupus Nephritis. *Ann Cardiol Angeiol (Paris).* 2015;64:S88.
6. Ginzler E, Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. *Baillieres Clin Rheumatol.* 1998;12:495–510.
7. Medeiros PB, Febrônio M V., Bonfá E, Borba EF, Takiuti AD, Silva CAA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. *Lupus.* 2009;18:38–43.
8. Bloomfield D. Secondary Amenorrhea. *Pediatr Rev.* 2006;27:113.
9. Oktem O, Guzel Y, Aydin E, Urman B. Ovarian Function and Reproductive Outcomes of Female Patients With Systemic Lupus Erythematosus and the Strategies to Preserve Their Fertility. 2017;72:196–210.
10. Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, et al. Three decades of progress in treating childhood-onset lupus nephritis. *Clin J Am Soc Nephrol.* 2011;6:2192–9.
11. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman E. Clinical and Laboratory Characteristics and Long-Term Outcome of Pediatric Systemic Lupus Erythematosus: A Longitudinal Study. *J Pediatr.* 2008;550–6.
12. Gottlieb BS, Ilowite NT. Systemic lupus erythematosus in children and adolescents. *Pediatr Rev.* 2006;27:323–30.
13. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. *J Clin Pathol.* 2003;56:481–90.
14. Bertsias G, Cervera R, Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis and Clinical Features. *Eular On-line Course Rheum Dis.* 2012;476–505.
15. Sinha R, Raut S. Pediatric lupus nephritis: Management update. *World J Nephrol.* 2014;3:16–23.

16. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 2012;64:2677–86.
17. Wan Ghazali WS, Mohd Daud SM, Mohammad N, Wong KK. Slicc damage index score in systemic lupus erythematosus patients and its associated factors. *Med (United States).* 2018;97.
18. Sinha R, Raut S. Pediatric lupus nephritis: Management update. *World J Nephrol.* 2014;3:16.
19. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res.* 2012;64:797–808.
20. Perhimpunan Reumatologi Indonesia. Rekomendasi Perhimpunan Reumatologi Indonesia untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. 2011. 1–54 p.
21. Taylor EB, Ryan MJ. Understanding mechanisms of hypertension in systemic lupus erythematosus. *Ther Adv Cardiovasc Dis.* 2017;11:20–32.
22. Lestari HI, Bahrin D. Hipertensi pada anak. In: Rachmadi D, Sekarwana N, Hilmanto D, Garna H, editors. Buku Ajar Nefrologi Anak. third edit. Jakarta: Badan Penerbit IDAI; 2017. p. 557–85.
23. Thakral A, Klein-Gitelman MS. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. *Rheumatol Ther.* 2016;3:209–19.
24. Kasjmir Y, Handono K, Wijaya LK, Hamijoyo L, Albar Z, Kalim H, et al. Rekomendasi Perhimpunan Reumatologi Indonesia untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. 2011. 1–54 p.
25. Klack K, Bonfa E, Neto EFB. Diet and nutritional aspects in systemic lupus erythematosus. *Rev Bras Reumatol.* 2012;52:384–408.
26. Olesińska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. *Reumatologia.* 2018;56:45–54.
27. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res.* 2012;64:797–808.
28. Oktadiano L, Prasetyo RV, Soemyarso NA, Noer MS. Predictors of mortality in children with nephritis lupus. *Paediatr Indones.* 2014;54:338–43.
29. Hernández-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. *Clin Exp Rheumatol.* 2001;19:395–401.
30. Mina R, Brunner HI. Pediatric Lupus—Are There Differences in Presentation, Genetics, Response to Therapy, and Damage Accrual Compared with Adult Lupus? *Rheum Dis Clin North Am.* 2010;36:53–80.
31. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et

- al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy, Asthma Clin Immunol.* 2013;9:1.
32. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis - Nephrology Rounds. *Clin J Am Soc Nephrol.* 2017;12:825–35.
33. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Vol. 69, *Annals of the Rheumatic Diseases.* 2010. p. 20–8.
34. Hahn BH, McMahon M, Wilkinson A, Wallace WD, Daikh DI, FitzGerald J, et al. American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis. *Arthritis Care Res.* 2012;64(6):797–808.
35. Chen YE, Korbert SM, Katz RS, Schwartz MM, Lewis EJ, Roberts JL, et al. Value of a complete or partial remission in severe lupus nephritis. *Clin J Am Soc Nephrol.* 2008;3:46–53.
36. Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: An achievable goal even with fewer steroids? Real-life data from a monocentric cohort. *Lupus Sci Med.* 2018;5:1–7.
37. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. *Ann Rheum Dis.* 2014;73:958–67.
38. Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. *Mediterr J Rheumatol.* 2017;28:14–22.
39. Wu JY, Yeh KW, Huang JL. Early predictors of outcomes in pediatric lupus nephritis: Focus on proliferative lesions. *Semin Arthritis Rheum.* 2014;43:513–20.
40. Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA. Persistent hypertension in lupus nephritis and the associated risk factors. *Clin Rheumatol.* 2015;34:93–7.
41. Der Mesropian PJ, Shaikh G, Cordero Torres E, Bilal A, Mathew RO. Antihypertensive therapy in nondiabetic chronic kidney disease: a review and update. *J Am Soc Hypertens.* 2018;12:154–81.
42. Al-Mayouf SM, AlAmeer A, Alfattani A, Alsonbul A. Outcome of childhood lupus nephritis in Saudi children. *Saudi J Kidney Dis Transpl.* 2017;28:1015–20.
43. Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcón GS, Solomon DH, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. *Arthritis Rheum.* 2011;63:1988–97.
44. Rovin BH, Alvarado A. The Kidney Biopsy in Lupus Nephritis: Is it Still Relevant? *Rheum Dis Clin North Am.* 2014;40:537.
45. Haladyj E, Cervera R. Do we still need renal biopsy in lupus nephritis? *Reumatologia.* 2016;54:61–6.

46. Saxena R, Mahajan T, Mohan C. Lupus nephritis: Current update. *Arthritis Res Ther.* 2011;13.
47. Listiyono F, Sumadiono S, Satria CD, Murni IK. Predictors of mortality in children with systemic lupus erythematosus. *Pediatr Indones.* 2019;52:1–6.
48. Hiraki LT, Feldman CH, Marty FM, Winkelmayer WC, Guan H, Costenbader KH. Serious Infection Rates among Children with Systemic Lupus Erythematosus Enrolled in Medicaid. *Arthritis Care Res.* 2017;1–20.
49. Al-Mayouf SM, Al-Jumaah S, Bahabri S, Al-Eid W. Infections associated with juvenile systemic lupus erythematosus. *Clin Exp Rheumatol.* 2001;19:748–50.
50. Shaikh N, Morone NE, Lopez J, Chianese J, Sangvai S, D'Amico F, et al. Does this child have a urinary tract infection? *JAMA.* 2007;298:2895–904.
51. Prajapati H. Urinary tract infections in children. *Paediatr Child Heal (United Kingdom).* 2018;28:318–23.
52. Ikatan Dokter Anak Indonesia. Pedomani Pelayanan Medis. 1st ed. Pudjiadi AH, Hegar B, Handryastuti S, Idris NS, Gandaputra EP, Harminiati ED, editors. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2009. 136 p.
53. Abdalla E, Jeyaseelan L, Ullah I, Abdwani R. Growth pattern in children with systemic lupus erythematosus. *Oman Med J.* 2017;32:284–90.
54. Sinicato NA, Postal M, Peres FA, Peliçari KDO, Marini R, Dos Santos ADO, et al. Obesity and cytokines in childhood-onset systemic lupus erythematosus. *J Immunol Res.* 2014;2014.
55. Sousa JR, Rosa ÉPC, Nunes IF de OC, Carvalho CMRG de. Effect of vitamin D supplementation on patients with systemic lupus erythematosus: a systematic review. *Rev Bras Reumatol (English Ed.)* 2017;57:466–71.
56. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-De-La-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. *Nutr Res Rev.* 2017;30:118–37.
57. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. *Arthritis Rheum.* 2010;62:9–21.
58. Mittal B V., Pendse S, Rennke HG, Singh AK. Hematuria in a patient with class IV lupus nephritis. *Kidney Int.* 2006;70:1182–6.
59. Ghaleb RM, Fahmy KA. Premature ovarian failure in systemic lupus erythematosus patients: is it related to cyclophosphamide treatment? *Egypt Rheumatol Rehabil.* 2019;46:85–91.
60. Dickerson JE, Dotzel E, Clark AF. Steroid-Induced Cataract : New Perspectives from In vitro and Lens Culture Studies. *Exp Eye Res.* 1997;65:507–16.
61. Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced Glaucoma: An avoidable irreversible blindness. *J Curr Glaucoma Pract.* 2017;11:67–72.
62. Avar Aydin PO, Shan J, Brunner HI, Mitsnefes MM. Blood pressure control over time in childhood-onset systemic lupus erythematosus. *Lupus.* 2018;27:657–64.
63. Stojan G, Petri M. The risk benefit ratio of glucocorticoids in SLE: have

- things changed over the past 40 years? *Curr Treatm Opt Rheumatol*. 2017;3:164–72.
64. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. *Indian Dermatol Online J*. 2014;5:416.
 65. Schmajuk G, Yazdany J. Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review. *Semin Arthritis Rheum*. 2011;40:559–75.
 66. Moorthy LN, Peterson MGE, Harrison MJ, Onel KB, Lehman TJA. Quality of life in children with systemic lupus erythematosus: A review. *Lupus*. 2007;16:663–9.
 67. Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. *Rheumatology*. 2007;46:895–8.
 68. Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. *Lupus*. 2000;9:601–6.